Table 1. Baseline characteristics in the participants with and without MAFLD.
| Characteristics | Non-MAFLD | MAFLD | P |
|---|---|---|---|
| n | 103,854 | 47,537 | |
| Age, years | 48.8±14.5 | 51.0±12.6 | <0.001 |
| Male | 82,808 (79.7) | 39,957 (84.1) | <0.001 |
| Education level | <0.001 | ||
| Junior high school or below | 76,700 (73.9) | 36,422 (76.6) | |
| Senior high school or higher | 27,154 (26.1) | 11,115 (23.4) | |
| Past/current smoking | 41,288 (39.8) | 20,591 (43.3) | <0.001 |
| Excessive alcohol consumption | 13,752 (13.2) | 8,373 (17.6) | <0.001 |
| Physical activity | 0.384 | ||
| Inactive | 15,050 (14.5) | 6,879 (14.5) | |
| Moderately active | 73,350 (70.6) | 33,455 (70.4) | |
| Active | 15,454 (14.9) | 7,203 (15.2) | |
| Family history of cancers | <0.001 | ||
| Yes | 4,369 (4.2) | 2,508 (5.3) | |
| No | 64,348 (62.0) | 28,618 (60.2) | |
| Unknown | 35,137 (33.8) | 16,411 (34.5) | |
| BMI, kg/m2 | 23.8±3.1 | 27.4±3.2 | <0.001 |
| WC, cm | 84.0±9.5 | 92.5±9.2 | <0.001 |
| SBP, mmHg | 126.6±20.1 | 135.8±20.5 | <0.001 |
| DBP, mmHg | 81.4±11.2 | 87.2±11.6 | <0.001 |
| FBG, mmol/L | 5.3±1.4 | 5.9±2.0 | <0.001 |
| TG, mmol/L | 1.4±1.0 | 2.2±1.5 | <0.001 |
| TC, mmol/L | 4.8±1.1 | 5.1±1.2 | <0.001 |
| LDL-C, mmol/L | 2.4±0.9 | 2.5±0.9 | <0.001 |
| HDL-C, mmol/L | 1.5±0.3 | 1.4±0.4 | <0.001 |
| hs-CRP, mg/dL | 0.8 (0.3, 2.0) | 1.4 (0.6, 3.2) | <0.001 |
| ALT, U/L | 17.0 (12.0, 23.0) | 22.7 (16.1, 32.0) | <0.001 |
| HBsAg positive | 2,986 (2.9) | 1,061 (2.2) | <0.001 |
Data are presented as mean ± standard deviation, median (interquartile range), or number (%) of participants with a condition. MAFLD, metabolic associated fatty liver disease; BMI, body mass index; WC, waist circumstance; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen.